Clinical Pharmacokinetics of Reboxetine, a Selective Norepinephrine Reuptake Inhibitor for the Treatment of Patients with Depression
- 1 December 2000
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 39 (6) , 413-427
- https://doi.org/10.2165/00003088-200039060-00003
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Pharmacokinetics of Reboxetine in Volunteers with Hepatic ImpairmentClinical Drug Investigation, 2000
- Pharmacokinetics of Single‐Dose Reboxetine in Volunteers with Renal InsufficiencyThe Journal of Clinical Pharmacology, 2000
- The Role of Norepinephrine in the Treatment of DepressionThe Journal of Clinical Psychiatry, 1999
- Metabolism of the Newer AntidepressantsClinical Pharmacokinetics, 1998
- P-2-76 Effect of lorazepam on the pharmacokinetics of reboxetine in healthy volunteersEuropean Neuropsychopharmacology, 1995
- Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein bindingBiopharmaceutics & Drug Disposition, 1995
- Stereoselective and species‐dependent kinetics of reboxetine in mouse and ratChirality, 1995
- Fluoxetine-Associated Potentiation of Calcium-Channel BlockersJournal of Clinical Psychopharmacology, 1991
- Comparison of the disposition and of the metabolic pattern of Reboxetine, a new antidepressant, in the rat, dog, monkey and manEuropean Journal of Drug Metabolism and Pharmacokinetics, 1991
- Alprazolam in End-Stage Renal Disease: I. PharmacokineticsThe Journal of Clinical Pharmacology, 1991